Senseonics announced the long-awaited FDA approval of its Eversense E3 implantable CGM, featuring a sensor that lasts up to six months. The company is also developing a one-year version of Eversense and a transmitter-less version, but the stock market is disappointed with its sales projections.

Omnipod 5 is the first tubeless automated insulin delivery system compatible with Dexcom’s G6 continuous glucose monitoring system to automatically adjust insulin levels.

In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.

Medtech Insight spoke to the manufacturers of the smallest commercially available insulin pump to learn more about how it works, the market factors impacting it, and how scaling up a business can throw up unexpected challenges.